ACROBiosystems Enhances GMP Production Capacity with New Facility Launch in Suzhou

ACROBiosystems Suzhou GMP Facility Expansion



In a pivotal move within the biopharmaceutical landscape, ACROBiosystems announced the completion of its Phase II expansion at the GMP facility in Suzhou, China, which took place in July 2026. This groundbreaking project has been designed to bolster the company's production capabilities and ensure a steady supply of essential raw materials critical for the manufacturing of cell and gene therapies.

Overview of the New Facility


The new facility features advanced operational lines for producing prokaryotic bulk solutions alongside cell bank production. This enhancement allows ACROBiosystems to ensure a complete end-to-end process for the GMP-grade core raw materials needed in commercial applications.

The Phase II expansion has already marked several achievements, notably completing trial productions and successfully manufacturing GMP products in multiple batches. This solidifies ACROBiosystems' commitment to enhancing the resilience and reliability of its supply chains across the globe.

Improved Production Capabilities


This expansion builds upon the foundations laid by the Phase I facility, which commenced operations in 2024. Since then, this initial phase succeeded in producing nearly 100 high-quality GMP-grade products, including key items like cytokines, antibodies, and magnetic beads, all necessary for cell activation and other applications. The additional capabilities provided by Phase II not only allow for an increase in production volumes but also optimize cost efficiencies through economies of scale.

The ACROBiosystems Suzhou facility is emblematic of a forward-thinking vision within the biopharmaceutical industry. The facility is designed with flexibility and resilience in mind, equipped to respond quickly to the dynamic demands of the global healthcare market. Looking forward, the company aims to leverage its independent production capabilities to strengthen partnerships across the biomedical landscape and enhance its quality management systems, ultimately accelerating drug development processes for its clients.

Facility Design and Compliance


The ACROBiosystems Suzhou GMP Intelligent Facility, which officially opened in June 2024, spans over 5.4 acres with a gross floor area surpassing 50,000 m². It features an intelligent, modular production design, equipped to handle a variety of complex manufacturing tasks, enabling it to cater to diverse customer needs for GMP-grade products. The facility not only adheres to stringent regulatory standards but is also Audit-Ready (ADR), capable of being assessed remotely or on-site, confirming compliance with various international regulations including those from the FDA, ISO GMP, and the Rx-360 International Pharmaceutical Supply Chain Consortium.

The facility is also equipped with independent GMP workshops dedicated to cell banking, bulk solution production, formulation, alongside a state-of-the-art 2,200 m² quality control laboratory. Its production capabilities allow for bulk solution production in capacities ranging from 10 to 500 liters.

Future Directions and Goals


This expansion is not merely about increasing capacity; it's about setting a new standard for quality and reliability in the biopharmaceutical supply chain. ACROBiosystems maintains an unwavering commitment to providing high-quality and innovative products, thus enabling its global partners in navigating the challenges of drug development and commercialization.

In conclusion, the Phase II launch at the ACROBiosystems Suzhou facility is a significant leap forward, reinforcing the company's position as a key player in the biopharmaceutical sector. Through continuous innovation and unwavering commitment to meeting regulatory standards, the company is poised to drive advancements in drug therapies that benefit global health.

With an increasing focus on quality, reliability, and customer support, ACROBiosystems is ready to meet the challenges of tomorrow’s biopharmaceutical industry head-on.

Topics Business Technology)

【About Using Articles】

You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.

【About Links】

Links are free to use.